Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 10/20 | 0.61 |
| ▸ | BACE1 | P56817 | 6/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1194141 | 0.89 | NPSR1 (0.58) | HSP90AA1BACE1NPSR1ALDH1A1HPGD | |
| SCHEMBL6227338 | 0.88 | NPSR1 (0.60) | HSP90AA1BACE1NPSR1ALDH1A1HPGD | |
| Hydrochloric Acid SCHEMBL7051973 | 0.85 | HSP90AA1 (0.67) | HSP90AA1BACE1ALDH1A1HTT | |
| Hydrochloric Acid SCHEMBL7049163 | 0.82 | HSP90AA1 (0.67) | HSP90AA1BACE1ALDH1A1HTT | |
| Hydrochloric Acid SCHEMBL7050579 | 0.81 | HSP90AA1 (0.62) | HSP90AA1BACE1ALDH1A1HTT | |
| SCHEMBL7624559 | 0.81 | GLA (0.56) | HSP90AA1BACE1NPSR1ALDH1A1HTT | |
| SCHEMBL7509553 | 0.81 | HSP90AA1 (0.65) | HSP90AA1BACE1ALDH1A1 | |
| Bromide SCHEMBL1193730 | 0.80 | GLA (0.58) | HSP90AA1BACE1NPSR1ALDH1A1HTT | |
| Hydrochloric Acid SCHEMBL1193848 | 0.80 | GLA (0.52) | HSP90AA1BACE1NPSR1ALDH1A1HTT | |
| Hydrochloric Acid SCHEMBL7162876 | 0.80 | HSP90AA1 (0.57) | HSP90AA1BACE1ALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2659933-A1 | Pharmaceutical combinations comprising specified age breaker and further drugs, i.a. antihypertensive drugs, antidiabetic drugs etc. | Torrent Pharmaceuticals Ltd. (IN) | 2013-11-06 | — | — | EP | claimed |
| JP-2011510067-A | — | — | 2011-03-31 | — | — | JP | claimed |
| US-20110034378-A1 | Pharmaceutical Combinations Comprising Specified Age Breaker and Further Drugs, I.A. Antihypertensive Drugs, Antidiabetic Drugs Etc. | TORRENT PHARMACEUTICALS LTD. (IN) | 2011-02-10 | — | — | US | claimed |
| EP-2254563-A2 | PHARMACEUTICAL COMBINATIONS COMPRISING SPECIFIED AGE BREAKER AND FURTHER DRUGS, I.A. ANTIHYPERTENSIVE DRUGS, ANTIDIABETIC DRUGS ETC | Torrent Pharmaceuticals Ltd. (IN) | 2010-12-01 | — | — | EP | claimed |
| WO-2009093264-A2 | PHARMACEUTICAL COMBINATIONS | TORRENT PHARMACEUTICALS LTD. (IN) | 2009-07-30 | — | — | WO | claimed |
| EP-1243581-B1 | Pyridinium compounds useful for the treatment of AGE-related diseases | TORRENT PHARMACEUTICALS LTD (IN) | 2005-07-13 | — | — | EP | claimed |
| US-6624178-B2 | Novel compounds of the pyridinium series useful for the management of diabetes and aging-related vascular complications, including kidney disease, nerve damage, atherosclerosis, retinopathy, dermatological disorders and | TORRENT PHARMACEUTICALS LTD. (IN) | 2003-09-23 | — | — | US | claimed |
| US-20030092744-A1 | Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof | TORRENT PHARMACEUTICALS LTD. | 2003-05-15 | — | — | US | claimed |
| EP-1304101-A1 | Composition and method for use of pyridinium derivatives in cosmetic and therapeutic applications | Torrent Pharmaceuticals Ltd (IN) | 2003-04-23 | — | — | EP | claimed |
| US-20030032660-A1 | Breaking preformed AGE | TORRENT PHARMACEUTICALS LTD. | 2003-02-13 | — | — | US | claimed |
| EP-1243581-A1 | Pyridinium compounds useful for the treatment of AGE-related diseases | Torrent Pharmaceuticals Ltd (IN) | 2002-09-25 | — | — | EP | claimed |
| US-20020103228-A1 | Composition and method for use of pyridinium derivatives in cosmetic and therapeutic applications | TORRENT PHARMACEUTICALS LTD. | 2002-08-01 | — | — | US | claimed |
| US-20010018524-A1 | Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof | TORRENT PHARMACEUTICALS LTD. (IN) | 2001-08-30 | — | — | US | claimed |
| EP-2659933-A1 | Pharmaceutical combinations comprising specified age breaker and further drugs, i.a. antihypertensive drugs, antidiabetic drugs etc. | Torrent Pharmaceuticals Ltd. (IN) | 2013-11-06 | — | — | EP | disclosed |
| US-20110034378-A1 | Pharmaceutical Combinations Comprising Specified Age Breaker and Further Drugs, I.A. Antihypertensive Drugs, Antidiabetic Drugs Etc. | TORRENT PHARMACEUTICALS LTD. (IN) | 2011-02-10 | — | — | US | disclosed |
| EP-1243581-B1 | Pyridinium compounds useful for the treatment of AGE-related diseases | TORRENT PHARMACEUTICALS LTD (IN) | 2005-07-13 | — | — | EP | disclosed |
| US-6462057-B1 | SUCH AS 1-(2-ETHOXY-2-OXOETHYL)-3-(METHANESULFONYLHYDRAZINO-CARBONYL)PYRIDINIUM BROMIDE; KIDNEY DISEASE, NERVE DAMAGE, ATHEROSCLEROSIS, RETINOPATHY, DERMATOLOGICAL DISORDERS AND DISCOLORATION OF TEETH | TORRENT PHARMACEUTICALS, LTD. (IN) | 2002-10-08 | — | — | US | disclosed |
| EP-1243581-A1 | Pyridinium compounds useful for the treatment of AGE-related diseases | Torrent Pharmaceuticals Ltd (IN) | 2002-09-25 | — | — | EP | disclosed |
| US-20020103228-A1 | Composition and method for use of pyridinium derivatives in cosmetic and therapeutic applications | TORRENT PHARMACEUTICALS LTD. | 2002-08-01 | — | — | US | disclosed |
| US-20010018524-A1 | Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof | TORRENT PHARMACEUTICALS LTD. (IN) | 2001-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010018524-A1 | Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof | AGER, GLA, RBP1 | HSP90AA1 4651/4885BACE1 368/4885NPSR1 4044/4885 |
| US-20030092744-A1 | Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof | AGER, REN, RBP4 | HSP90AA1 4762/4885BACE1 134/4885NPSR1 3831/4885 |
| US-20030032660-A1 | Breaking preformed AGE | AGER, GPX1, RBP1 | HSP90AA1 4802/4885BACE1 76/4885NPSR1 3612/4885 |
| US-20020103228-A1 | Composition and method for use of pyridinium derivatives in cosmetic and therapeutic applications | PNPO, PRDX5, PLPBP | HSP90AA1 4863/4885BACE1 1232/4885NPSR1 2377/4885 |
| US-20110034378-A1 | Pharmaceutical Combinations Comprising Specified Age Breaker and Further Drugs, I.A. Antihypertensive Drugs, Antidiabetic Drugs Etc. | AGER, F12, DPP4 | HSP90AA1 1980/4885BACE1 1039/4885NPSR1 660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.